PMI Sanctioned by DTI for Violating Philippine Regulations: IQOS ILUMA Limited Edition Advertising Halted

Apr.24.2025
PMI Sanctioned by DTI for Violating Philippine Regulations: IQOS ILUMA Limited Edition Advertising Halted
On April 23, 2025, the Philippine Department of Trade and Industry (DTI) formally charged PMFTC, the Philippine affiliate of Philip Morris International, with violating RA11900, the Vaporized Nicotine and Non-Nicotine Products Regulation Act. The DTI ordered an immediate halt to all promotional activities related to the IQOS ILUMA x Steve Aoki limited edition product.

Key points

1.Philip Morris International's (PMI) Philippine subsidiary (PMFTC) has been formally charged with illegal promotional activities: On April 23, 2025, the Philippine DTI filed formal charges against PMFTC for violating Section 12(d) of the RA11900 Act. The reason cited was the company's promotion of heated tobacco products at the "Steve Aoki Live" event.

 

2.The Department of Trade and Industry (DTI) has ordered PMFTC to immediately cease all online and offline advertising related to the IQOS ILUMA x Steve Aoki limited edition.

 

3.Violation content includes images and information that encourage consumption: the complained promotional materials which showcase heated tobacco products, encourage consumption, contravene RA11900 regulations prohibiting the promotion of tobacco product use.

 

4.Official demands comprehensive rectification and removal of content: DTI requires PMFTC to immediately take rectification measures, and delete all graphic and textual content promoting tobacco consumption, especially content targeting minors.


According to the official website of the Department of Trade and Industry (DTI) of the Philippines, on April 23, 2025, the Special Task Force Office for the Vaporized Nicotine and Non-Nicotine Products of the Department of Trade and Industry (DTI) formally filed charges against Philip Morris International (PMI) Philippines branch (PMFTC) and issued a Preliminary Order and/or Preventive Measures Order (POPMO). The company has been found to have violated Republic Act No. 11900, also known as the Vaporized Nicotine and Non-Nicotine Products Regulation Act, specifically Section 12(d).

 

This order will take immediate effect, prohibiting PMFTC from promoting and advertising its IQOS ILUMA x Steve Aoki limited edition products both offline and online.

 

This enforcement action stems from a complaint received on April 15, 2025, by the Tobacco Control and Public Health Organization Alliance, accusing PMFTC of promoting its IQOS ILUMA series products during the "Steve Aoki Live" event scheduled to take place at the Xylo club in Bonifacio Global City (BGC), Taguig on April 26, 2025.

 

The promotional materials displayed the heated tobacco product (HTP) device, encouraging consumers to use HTP tobacco products, directly violating Section 12(d) of RA11900 which prohibits "any promotion of posts, messages, or images encouraging the use or purchase of such products".

 

PMFTC confirmed in a letter submitted to the DTI that they did indeed collaborate with artist Steve Aoki to launch the product series.

 

The DTI OSMV has requested PMFTC to immediately take appropriate corrective measures and fully comply with RA11900 and all relevant regulations. At the same time, the company is required to swiftly remove all digital/online or offline advertisements, marketing materials, information, and images, particularly those targeting minors or portraying tobacco consumption as an "ideal lifestyle" content.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
FDA’s Center for Tobacco Products is reshaping how it approaches tobacco product review. Based on 2Firsts’ on-site reporting in New York and Washington, this report traces CTP’s emerging direction: stronger links between PMTA and tobacco harm reduction, more category-specific review, greater emphasis on decision-relevant science, more predictable timelines and expanded use of sPMTA for product modifications. CTP also acknowledged major constraints, including just nine PMTA review teams, persistent backlogs and limits on hiring capacity.
Regulations
Oct.08
FRE and ALP Push Modern Oral to 48% of Q2 Sales as Turning Point Brands Changes CEO and Lowers Profit-Guidance Ceiling
FRE and ALP Push Modern Oral to 48% of Q2 Sales as Turning Point Brands Changes CEO and Lowers Profit-Guidance Ceiling
Turning Point Brands said Executive Chairman David E. Glazek will become CEO on October 1, replacing Graham Purdy, who is stepping down for personal reasons. The company narrowed its 2026 adjusted EBITDA outlook to $70 million-$80 million from $70 million-$90 million while maintaining Modern Oral gross sales guidance of $330 million-$350 million and net sales guidance of $260 million-$270 million. In the second quarter, Modern Oral net sales rose 128% to $68.4 million and accounted for 48% of company-wide net sales. Adjusted EBITDA fell 50% year over year. TPB shares closed about 10% lower on September 21.
Market
Sep.22 by 2Firsts Perspectives
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane’s 2026 update of its living review on electronic cigarettes for smoking cessation included 80 randomized controlled trials involving 29,861 adult smokers, with nine trials added in this update. The review retained its high-certainty conclusion that nicotine e-cigarettes increase smoking cessation rates compared with nicotine replacement therapy. In absolute terms, about 10 in 100 people using nicotine e-cigarettes may quit smoking for at least six months, compared with about 6 in 100 using NRT. The review found no clear difference in serious adverse event rates between the two groups, while longer-term safety and the relative effectiveness of newer device types remain less certain.
Sep.07
Latest UK ONS Data: Vaping Rate Edges Down to 9.9% in 2025, a Year After Overtaking Cigarette Smoking
Latest UK ONS Data: Vaping Rate Edges Down to 9.9% in 2025, a Year After Overtaking Cigarette Smoking
Vaping prevalence in Great Britain edged down to 9.9% in 2025 from 10.0% in 2024, with the number of adult users holding at approximately 5.4 million for a second consecutive year, according to the Office for National Statistics (ONS). E-cigarette use had risen from 6.4% in 2020 to 10.0% in 2024, when it exceeded cigarette smoking prevalence for the first time. Cigarette smoking continued to decline to 8.7% in 2025, widening the gap to 1.2 percentage points. Daily vaping declined slightly, while usage among adults aged 25–34 increased despite falling rates in other age groups.
DATA
Oct.14
BAT CFO Dragos Constantinescu Takes Office, Returning After Seven Years and Former Asahi Europe Leadership Role
BAT CFO Dragos Constantinescu Takes Office, Returning After Seven Years and Former Asahi Europe Leadership Role
Dragos Constantinescu has officially taken up his role as Chief Financial Officer and Executive Director at British American Tobacco (BAT). He previously spent 16 years at BAT across finance and general management roles in Europe before joining Asahi in 2019 and becoming CEO of Asahi Europe & International in 2025. His return comes as BAT continues to advance its “A Better Tomorrow” transformation.
BAT
Sep.01
FDA Appoints Former Tobacco Enforcement Deputy Jessica Zeller as Director as Agency Weighs PMTA Framework Changes
FDA Appoints Former Tobacco Enforcement Deputy Jessica Zeller as Director as Agency Weighs PMTA Framework Changes
The U.S. Food and Drug Administration (FDA) has named Jessica Zeller director of the Center for Tobacco Products' (CTP) Office of Compliance and Enforcement (OCE), effective November 1, 2026. Zeller, the office's inaugural deputy director, returns from medical device manufacturer Edwards Lifesciences with more than 20 years of regulatory and legal experience. The appointment follows CTP leadership changes and adjustments to tobacco regulation. Bret Koplow became permanent CTP director in September; the FDA revised enforcement priorities for unauthorized e-cigarettes and nicotine pouches in May and announced faster PMTA review procedures. On September 28, the agency said it would evaluate changes to the existing PMTA regulatory framework, including potential rulemaking to replace it.
FDA
Oct.20 by 2Firsts Perspectives